Close Menu

NEW YORK – Co-Diagnostics' joint manufacturing venture, CoSara Diagnostics, has received regulatory clearance from the Central Drug Standard Control Organization in India for five in vitro diagnostic tests.

The five tests are molecular diagnostic assay kits, branded CoSara Saragene, are for the detection of tuberculosis, malaria, hepatitis B and hepatitis C viruses, and human papillomavirus. They can now be manufactured and sold from the CoSara facility in Ranoli, India.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.